Adicet Bio, Inc.
Adicet Bio
200 Constitution Drive
Menlo Park
California
94025
United States
Website: http://www.adicetbio.com/
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
112 articles about Adicet Bio, Inc.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 01, 2022
10/1/2022
Adicet Bio, Inc. announced it granted inducement awards on September 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022.
-
Adicet Bio to Present at Upcoming September 2022 Investor Conferences
9/7/2022
Adicet Bio, Inc. announced that company management will participate in two upcoming investor conferences in September.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2022
8/31/2022
Adicet Bio, Inc. announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022.
-
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
8/10/2022
Adicet Bio, Inc. today reported financial results and operational highlights for the second quarter ended June 30, 2022.
-
Adicet Bio to Present at Upcoming Investor Conferences
8/1/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 29, 2022
7/29/2022
Adicet Bio, Inc., a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, announced it granted inducement awards on July 29, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to seven individuals hired by Adicet in July 2022.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022
7/1/2022
Adicet Bio, Inc., a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, announced it granted inducement awards on June 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to ten individuals hired by Adicet in June 2022.
-
Adicet Bio to Present at Upcoming Investor Conferences - June 21, 2022
6/21/2022
Adicet Bio, Inc. announced that company management will participate in two upcoming investor conferences in June.
-
Legend Biotech and J&J, Adicet Bio, Curis and Immutep present optimistic early and mid-stage results at ASCO. -
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
6/6/2022
ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin’s Lymphoma (NHL), as of May 31, 2022 data-cut date.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 03, 2022
6/3/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, announced it granted inducement awards on May 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in May 2022.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more. -
Genentech announced new data related to its investigational CD20xCD3 T-cell engaging bispecific antibody intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). -
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
5/26/2022
Adicet Bio, Inc. (Nasdaq: ACET), today announced that an abstract detailing updated safety and efficacy data from the Company’s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphoma (NHL) was made available as part of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Adicet Bio to Present at Upcoming Investor Conferences - May 18, 2022
5/18/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, announced that company management will participate in two upcoming investor conferences in May and June.
-
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
5/12/2022
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2022.
-
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
5/5/2022
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 04, 2022
5/4/2022
Adicet Bio, Inc. announced it granted inducement awards on April 29, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in April 2022.
-
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
4/27/2022
Adicet Bio, Inc. (Nasdaq: ACET), today announced that updated safety and efficacy data from the Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphoma (NHL) will be delivered as an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
4/19/2022
Adicet Bio, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead program ADI-001.